Moderna Inc. and Merck & Co Inc. reported that a late-stage Phase 3 trial of a personalized mRNA melanoma vaccine reduced skin cancer recurrence.
The results mark a potential shift in oncology treatment by utilizing mRNA technology to create patient-specific therapies. This breakthrough suggests that personalized vaccines could significantly lower the risk of cancer returning after initial treatment.
Investors reacted to the news on Wednesday. Shares of Moderna rose between 90% and 93% [1], reaching approximately $121.90 [1]. The surge represents one of the company's most significant single-day gains.
The vaccine was developed through a partnership between Moderna and Merck. The trial met its primary endpoints by lowering the recurrence of melanoma in participants [2], [3]. This outcome validates the approach of using mRNA to instruct the immune system to recognize and attack specific mutations found in a patient's tumor.
While the trial focused on melanoma, the success of the personalized mRNA platform could have implications for other types of cancer. The companies are now positioned to move toward regulatory filings based on the Phase 3 data [2].
Market analysts said that the share-price enthusiasm stems from the interpreted breakthrough in cancer therapy [2], [3]. The personalized nature of the vaccine requires sequencing the patient's tumor to identify unique mutations, a process that distinguishes this treatment from traditional one-size-fits-all vaccines.
Both companies saw stock increases following the announcement, though Moderna's gain was the most pronounced [1], [4]. The results were reported across U.S. equity markets on Wednesday [2], [4].
“A late-stage Phase 3 trial of a personalized mRNA melanoma vaccine reduced skin cancer recurrence.”
The success of this Phase 3 trial signals a transition for mRNA technology from infectious disease prevention to chronic disease treatment. By proving that personalized vaccines can reduce cancer recurrence, Merck and Moderna are establishing a blueprint for 'precision oncology.' If approved, this could shift the standard of care for melanoma patients, moving from general immunotherapy to a hybrid model of generic drugs combined with patient-specific mRNA vaccines.
